Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.16
IART's Cash to Debt is ranked lower than
90% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. IART: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
IART' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.43 Max: No Debt
Current: 0.16
Equity to Asset 0.45
IART's Equity to Asset is ranked lower than
73% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. IART: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
IART' s Equity to Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.54 Max: 0.95
Current: 0.45
0.29
0.95
Interest Coverage 3.89
IART's Interest Coverage is ranked lower than
88% of the 230 Companies
in the Global Medical Devices industry.

( Industry Median: 71.03 vs. IART: 3.89 )
Ranked among companies with meaningful Interest Coverage only.
IART' s Interest Coverage Range Over the Past 10 Years
Min: 1.58  Med: 3.38 Max: 5.53
Current: 3.89
1.58
5.53
F-Score: 6
Z-Score: 2.96
M-Score: -2.58
WACC vs ROIC
6.48%
5.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.09
IART's Operating margin (%) is ranked higher than
70% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. IART: 10.09 )
Ranked among companies with meaningful Operating margin (%) only.
IART' s Operating margin (%) Range Over the Past 10 Years
Min: -0.44  Med: 8.95 Max: 14.33
Current: 10.09
-0.44
14.33
Net-margin (%) 6.09
IART's Net-margin (%) is ranked higher than
64% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. IART: 6.09 )
Ranked among companies with meaningful Net-margin (%) only.
IART' s Net-margin (%) Range Over the Past 10 Years
Min: -2.03  Med: 4.6 Max: 8.97
Current: 6.09
-2.03
8.97
ROE (%) 7.68
IART's ROE (%) is ranked higher than
63% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. IART: 7.68 )
Ranked among companies with meaningful ROE (%) only.
IART' s ROE (%) Range Over the Past 10 Years
Min: -2.86  Med: 8.46 Max: 13.9
Current: 7.68
-2.86
13.9
ROA (%) 3.28
IART's ROA (%) is ranked higher than
62% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.31 vs. IART: 3.28 )
Ranked among companies with meaningful ROA (%) only.
IART' s ROA (%) Range Over the Past 10 Years
Min: -1.44  Med: 3.29 Max: 6.71
Current: 3.28
-1.44
6.71
ROC (Joel Greenblatt) (%) 20.59
IART's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. IART: 20.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IART' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1.1  Med: 17.48 Max: 36.6
Current: 20.59
-1.1
36.6
Revenue Growth (3Y)(%) -5.30
IART's Revenue Growth (3Y)(%) is ranked lower than
73% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. IART: -5.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IART' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.3  Med: 22.1 Max: 55
Current: -5.3
-5.3
55
EBITDA Growth (3Y)(%) -3.40
IART's EBITDA Growth (3Y)(%) is ranked lower than
63% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. IART: -3.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IART' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -38  Med: 9.45 Max: 35
Current: -3.4
-38
35
EPS Growth (3Y)(%) -49.10
IART's EPS Growth (3Y)(%) is ranked lower than
95% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. IART: -49.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IART' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.1  Med: -3.05 Max: 27.1
Current: -49.1
-49.1
27.1
» IART's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

IART Guru Trades in Q4 2015

Richard Snow 299,047 sh (+6.79%)
Ken Fisher 552,195 sh (+0.11%)
Paul Tudor Jones Sold Out
David Dreman Sold Out
Joel Greenblatt Sold Out
Jim Simons 51,330 sh (-6.55%)
Steven Cohen 405,100 sh (-10.65%)
» More
Q1 2016

IART Guru Trades in Q1 2016

Paul Tudor Jones 3,442 sh (New)
David Dreman 22,258 sh (New)
Steven Cohen 435,400 sh (+7.48%)
Ken Fisher 544,895 sh (-1.32%)
Richard Snow 217,125 sh (-27.39%)
Jim Simons 33,330 sh (-35.07%)
» More
Q2 2016

IART Guru Trades in Q2 2016

RS Investment Management 709,503 sh (New)
Jim Simons 102,530 sh (+207.62%)
David Dreman Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 503,365 sh (-7.62%)
Richard Snow 174,405 sh (-19.68%)
Steven Cohen 258,400 sh (-40.65%)
» More
Q3 2016

IART Guru Trades in Q3 2016

Paul Tudor Jones 8,005 sh (New)
Ken Fisher 526,405 sh (+4.58%)
Steven Cohen 100,000 sh (unchged)
Steven Cohen Sold Out
Richard Snow 146,930 sh (-15.75%)
Jim Simons 19,030 sh (-81.44%)
» More
» Details

Insider Trades

Latest Guru Trades with IART

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:MASI, NAS:NUVA, OTCPK:EKTAY, NAS:LIVN, NYSE:NVRO, NAS:WMGI, NYSE:PEN, NYSE:GMED, OTCPK:NHNKY, NAS:ZLTQ, NAS:BABY, NAS:INGN, NAS:ABMD, OTCPK:IOBCF, NAS:CNMD, OTCPK:CHEOY, NAS:MDXG, NAS:CYNO, NAS:SPNC, NAS:VASC » details
Traded in other countries:IL3.Germany,
Integra Lifesciences Holdings Corp is engaged in the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments.

Integra Lifesciences Holdings Corp was incorporated in Delaware in 1989. The Company develops, manufactures and market cost-effective surgical implants and medical instruments. Its products are used mainly in neurosurgery, extremity reconstruction, orthopedics and general surgery. The Company sells its products directly through various sales forces and through various distribution channels. The Company currently manufactures and sells its products in five reportable business segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. Its U.S. Neurosurgery sales organization sells a full line of products specifically for neurosurgery and neuro critical care. The Company has products for each step of a cranial procedure and the care of the patient after surgery. Its key products include dural repair products, tissue ablation equipment, intracranial monitoring equipment, cranial stabilization equipment, and cerebral spinal fluid management devices. It sells equipment used in the neurosurgery operating room and neurosurgery intensive care unit. It sells its products through directly employed sales representatives. U.S. Extremities; the Company define extremity reconstruction to mean the repair of soft tissue and the orthopedic reconstruction of bone in the foot, ankle and leg below the knee, and the hand, wrist, elbow and shoulder. Its key products include bone and joint fixation devices, implants and instruments for osteoarthritis, rheumatoid arthritis, wrist and shoulder arthroplasty, carpal tunnel syndrome, and cubital tunnel syndrome. Other key products include its regenerative medicine devices for the treatment of acute and chronic wounds, peripheral nerve repair and protection and tendon repair, and bone graft substitutes. The Company sells its products through a direct sales organization and through specialty distributors focused on their respective surgical disciplines. Its U.S. Instruments business portfolio includes over 60,000 instrument patterns and surgical products, including hospitals, surgery centers, and physician, dental and veterinary offices. In addition to selling hand-held instruments, it sells surgical headlight systems and table-mounted retractors. Its brands includes Jarit, Miltex, Padgett, Ruggles, Luxtec and Omni-Tract. The Company's U.S. Spine and Other segment offers comprehensive spinal fusion technologies that surgeons use along the full length of the spine, as well as differentiated offering of related orthobiologics. This segment also includes private-label sales of a broad set of its regenerative medicine technologies. The International segment sells similar products, but they are managed through Europe, Middle East and Africa, Latin/South America, Asia-Pacific, Australia, New Zealand and Canada. The Company's trademarks include AccuDrain, Accell, Accell Evo3, Advansys, Atoll , Ascension, Bold, Budde, Buzz , Camino, CRW, Coral, CUSA, Daytona, DenLite, Dur

Ratios

vs
industry
vs
history
P/E(ttm) 47.98
IART's P/E(ttm) is ranked lower than
74% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 24.52 vs. IART: 47.98 )
Ranked among companies with meaningful P/E(ttm) only.
IART' s P/E(ttm) Range Over the Past 10 Years
Min: 15.26  Med: 31.51 Max: 6446
Current: 47.98
15.26
6446
Forward P/E 19.61
IART's Forward P/E is ranked higher than
56% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 22.57 vs. IART: 19.61 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 48.55
IART's PE(NRI) is ranked lower than
72% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 25.09 vs. IART: 48.55 )
Ranked among companies with meaningful PE(NRI) only.
IART' s PE(NRI) Range Over the Past 10 Years
Min: 15.26  Med: 32.42 Max: 537.81
Current: 48.55
15.26
537.81
Price/Owner Earnings (ttm) 109.20
IART's Price/Owner Earnings (ttm) is ranked lower than
88% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 31.56 vs. IART: 109.20 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
IART' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.21  Med: 26.03 Max: 4780.56
Current: 109.2
8.21
4780.56
P/B 3.43
IART's P/B is ranked lower than
56% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. IART: 3.43 )
Ranked among companies with meaningful P/B only.
IART' s P/B Range Over the Past 10 Years
Min: 1.21  Med: 2.35 Max: 5.46
Current: 3.43
1.21
5.46
P/S 2.95
IART's P/S is ranked higher than
52% of the 351 Companies
in the Global Medical Devices industry.

( Industry Median: 3.42 vs. IART: 2.95 )
Ranked among companies with meaningful P/S only.
IART' s P/S Range Over the Past 10 Years
Min: 0.79  Med: 1.68 Max: 4.65
Current: 2.95
0.79
4.65
PFCF 30.95
IART's PFCF is ranked lower than
66% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.15 vs. IART: 30.95 )
Ranked among companies with meaningful PFCF only.
IART' s PFCF Range Over the Past 10 Years
Min: 6.16  Med: 24.5 Max: 229.33
Current: 30.95
6.16
229.33
POCF 21.78
IART's POCF is ranked lower than
63% of the 145 Companies
in the Global Medical Devices industry.

( Industry Median: 20.79 vs. IART: 21.78 )
Ranked among companies with meaningful POCF only.
IART' s POCF Range Over the Past 10 Years
Min: 5.37  Med: 18.82 Max: 32.17
Current: 21.78
5.37
32.17
EV-to-EBIT 34.18
IART's EV-to-EBIT is ranked lower than
73% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 21.24 vs. IART: 34.18 )
Ranked among companies with meaningful EV-to-EBIT only.
IART' s EV-to-EBIT Range Over the Past 10 Years
Min: -349.8  Med: 22 Max: 384
Current: 34.18
-349.8
384
EV-to-EBITDA 19.84
IART's EV-to-EBITDA is ranked lower than
65% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 16.23 vs. IART: 19.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
IART' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.1  Med: 15.4 Max: 37.1
Current: 19.84
8.1
37.1
Shiller P/E 68.57
IART's Shiller P/E is ranked lower than
69% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 48.58 vs. IART: 68.57 )
Ranked among companies with meaningful Shiller P/E only.
IART' s Shiller P/E Range Over the Past 10 Years
Min: 17.3  Med: 37.83 Max: 214.11
Current: 68.57
17.3
214.11
Current Ratio 3.17
IART's Current Ratio is ranked higher than
62% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. IART: 3.17 )
Ranked among companies with meaningful Current Ratio only.
IART' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 4.24 Max: 19.4
Current: 3.17
0.81
19.4
Quick Ratio 1.81
IART's Quick Ratio is ranked lower than
52% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 1.88 vs. IART: 1.81 )
Ranked among companies with meaningful Quick Ratio only.
IART' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 2.62 Max: 18
Current: 1.81
0.46
18
Days Inventory 224.45
IART's Days Inventory is ranked lower than
74% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. IART: 224.45 )
Ranked among companies with meaningful Days Inventory only.
IART' s Days Inventory Range Over the Past 10 Years
Min: 175.51  Med: 206.45 Max: 250.68
Current: 224.45
175.51
250.68
Days Sales Outstanding 52.55
IART's Days Sales Outstanding is ranked higher than
70% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. IART: 52.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
IART' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.48  Med: 54.95 Max: 74.01
Current: 52.55
50.48
74.01
Days Payable 40.18
IART's Days Payable is ranked lower than
66% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. IART: 40.18 )
Ranked among companies with meaningful Days Payable only.
IART' s Days Payable Range Over the Past 10 Years
Min: 33.15  Med: 38.34 Max: 55.45
Current: 40.18
33.15
55.45

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.70
IART's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. IART: -9.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IART' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.8  Med: -3.3 Max: 3.1
Current: -9.7
-18.8
3.1

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.90
IART's Price/Projected FCF is ranked lower than
64% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. IART: 2.90 )
Ranked among companies with meaningful Price/Projected FCF only.
IART' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.66  Med: 1.59 Max: 10.03
Current: 2.9
0.66
10.03
Price/Median PS Value 1.78
IART's Price/Median PS Value is ranked lower than
85% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. IART: 1.78 )
Ranked among companies with meaningful Price/Median PS Value only.
IART' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.58  Med: 1.79 Max: 5.07
Current: 1.78
0.58
5.07
Earnings Yield (Greenblatt) (%) 2.93
IART's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. IART: 2.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IART' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 4.5 Max: 8.4
Current: 2.93
0.3
8.4
Forward Rate of Return (Yacktman) (%) 3.09
IART's Forward Rate of Return (Yacktman) (%) is ranked lower than
65% of the 120 Companies
in the Global Medical Devices industry.

( Industry Median: 8.58 vs. IART: 3.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IART' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -13.6  Med: 20.8 Max: 1210.5
Current: 3.09
-13.6
1210.5

More Statistics

Revenue (TTM) (Mil) $977.6
EPS (TTM) $ 1.58
Beta0.69
Short Percentage of Float12.50%
52-Week Range $54.75 - 88.86
Shares Outstanding (Mil)37.39

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 1,000 1,081
EPS ($) 3.47 3.93
EPS w/o NRI ($) 3.47 3.93
EPS Growth Rate
(3Y to 5Y Estimate)
13.00%
Dividends Per Share ($)
» More Articles for IART

Headlines

Articles On GuruFocus.com
SeaSpine: A Pure-Play Medical Spinoff Jul 22 2015 
WEEKLY CFO SELLS HIGHLIGHT: LMT, WCG, GRPN, IART, CNK Aug 26 2013 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 10,0 Mar 09 2011 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 125,100 Shares Mar 08 2011 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 5,32 Dec 08 2010 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 100,000 Shares Dec 03 2010 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 100,000 Shares Nov 04 2010 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 100, Nov 04 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) Oct 28 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
Hedge Funds Are Being Drawn Back Into Integra Lifesciences Holdings Corp (IART) Nov 28 2016
ACCUREXA, INC. (ACXA) and Other Medical Device Companies Add Value for Patients and Investors Nov 28 2016
Integra LifeSciences Holdings Corp. breached its 50 day moving average in a Bullish Manner : IART-US... Nov 22 2016
Integra LifeSciences to Present at the 28th Annual Piper Jaffray Healthcare Conference Nov 21 2016
Small-Cap Rally Offers Investors Alternatives to Big-Cap Multinationals Nov 18 2016
ETF’s with exposure to Integra LifeSciences Holdings Corp. : November 8, 2016 Nov 08 2016
Integra LifeSciences Holdings Corp. :IART-US: Earnings Analysis: Q3, 2016 By the Numbers : November... Nov 07 2016
INTEGRA LIFESCIENCES HOLDINGS CORP Financials Nov 03 2016
Integra (IART) Catches Eye: Stock Adds 6% in Session Oct 31 2016
Integra (IART) Posts Q3 Earnings & Sales Beat, Margins Up Oct 28 2016
Integra upgraded by Lake Street Oct 28 2016
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 10-Q, Quarterly Report Oct 28 2016
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K/A, Completion of Acquisition or Disposition of... Oct 28 2016
Edited Transcript of IART earnings conference call or presentation 27-Oct-16 8:30pm GMT Oct 27 2016
Integra beats Street 3Q forecasts Oct 27 2016
Integra beats Street 3Q forecasts Oct 27 2016
Integra LifeSciences Announces Plans for a Two-For-One Stock Split and Increase in Authorized Shares Oct 27 2016
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Other Events Oct 27 2016
Integra LifeSciences Reports Third Quarter 2016 Financial Results Oct 27 2016
Integra LifeSciences Announces Plans for a Two-For-One Stock Split and Increase in Authorized Shares Oct 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)